Kamada (KMDA) is a Healthcare · Drug Manufacturers - Specialty & Generic company listed on NASDAQ. Price $8.85 (+2.08%), Market cap $0.49B, P/E ratio 24.14, 52-week low–high $6.60 ~ $9.31.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite. The company also distribute
Financial statements, price targets, institutional (13F) holdings and related news for Kamada are updated in real time on BlackAll Trade.
Kamada trades at $8.85 (+2.08%). Real-time quotes and charts are available on BlackAll Trade.
Kamada has a market cap of about $0.49B. Its P/E ratio is 24.14.
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kid